Replies to post #521997 on NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

Novocure is a cash rush operating company with revenues. Of course NWBO is a company approaching that stage but is not yet there, should be there soon.

The US FDA appears to me to be well aware of DCVax-L and it’s challenges as indicated in the side article on ECA’s and certain references therein to trials that would be exactly like the DCVax-L trial. I don’t believe it is likely that DCVax-L will lack approval in any of the markets in which it had a trial and I believe the approval will be expedited once all the details are resolved and filed. Just IMHO.

[LearningEveryTrade]

US is dominant market because of very high prices, so, the numbers are skewed a bit. Your a numbers guy, you know that.

Nonocure does have 'device' approved. Revenue, yes. Hence, able to fund more trials. NWBO will take the same route when they have the impending approval and revenue generation over the coming years.

The TTF trials will be interesting to see if they hurt healthy cells division.